Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemnifosbuvir + ruzasvir
- Development stage
- Phase 3
- Lead developer
- Atea Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bemnifosbuvir + ruzasvir is an investigational, oral, once-daily fixed-dose combination therapy for the treatment of chronic hepatitis C virus (HCV) infection. Bemnifosbuvir is a purine nucleotide prodrug that inhibits viral replication by impairing the HCV RNA-dependent RNA polymerase (NS5B), while ruzasvir is an NS5A inhibitor with potent pan-genotypic antiviral activity. The combination has demonstrated synergistic antiviral effects in vitro and robust efficacy in clinical trials, including high sustained virologic response rates (SVR12) after 8 weeks of treatment. Both agents have favorable safety profiles and low risk for drug-drug interactions. The regimen is being developed by Atea Pharmaceuticals and has advanced to Phase 3 clinical trials for HCV[1][4][6][7].
- Other names
- ruzasvir + BEM
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on bemnifosbuvir + ruzasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemnifosbuvir + ruzasvir.